Lyrica Capsule
Product Images NDC 58151-237

Product Visual Gallery

This gallery contains 23 technical images submitted to the FDA as part of the official labeling for Lyrica (NDC 58151-237). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Viatris Specialty Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Cockcroft And Gault Equation (Image 01)

An illustration showing the formula for calculating creatinine clearance (CLCr). The formula includes age in years, weight in kilograms, serum creatinine in mg/dL, and a multiplication factor of 0.85 for female patients.*

FDA Label Image

Pregabalin Structural Formula (Image 02)

Chemical structure of pregabalin, the active ingredient in Lyrica. The diagram shows the molecular arrangement including carboxyl, amine groups, and hydrocarbon side chains characteristic of pregabalin.*

FDA Label Image

Figure 1: Patients Achieving Various Levels Of Improvement In Pain Intensity – Study Dpn 1 (Image 03)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at 200 mg, 100 mg, and 25 mg taken three times a day, compared to a placebo.*

FDA Label Image

Figure 2: Patients Achieving Various Levels Of Improvement In Pain Intensity– Study Dpn 2 (Image 04)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin 100 mg three times a day with placebo. The y-axis represents percent of patients improved from 0 to 100, and the x-axis represents percent improvement in pain from baseline, including thresholds such as ≥10%, ≥20%, ≥30%, ≥40%, ≥50%, ≥60%, ≥70%, ≥80%, and ≥90%. Pregabalin shows a higher percentage of patients improved across these thresholds compared to placebo.*

FDA Label Image

Figure 3: Patients Achieving Various Levels Of Improvement In Pain Intensity– Study Phn 1 (Image 05)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. The chart compares Pregabalin capsules at 75 mg, 150 mg, and 300 mg doses taken two times a day, against placebo, illustrating varying levels of patient-reported pain improvement.*

FDA Label Image

Figure 4: Patients Achieving Various Levels Of Improvement In Pain Intensity – Study Phn 2 (Image 06)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, illustrating patient improvement over varying pain reduction percentages.*

FDA Label Image

Figure 5: Patients Achieving Various Levels Of Improvement In Pain Intensity– Study Phn 3 (Image 07)

A line graph showing the percent of patients improved plotted against percent improvement in pain from baseline. The graph compares three groups: patients taking Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and a placebo group. The vertical axis represents percent of patients improved, while the horizontal axis represents percent improvement in pain from baseline, ranging from over 0 to 100 percent.*

FDA Label Image

Figure 6: Responder Rate By Adjunctive Epilepsy Study (Image 08)

Bar chart comparing responder rates (%) in two clinical studies labeled Study E1 and Study E3. Study E1 shows results for placebo and pregabalin doses 50 mg/day to 600 mg/day with increasing responder rates. Study E3 shows placebo and pregabalin doses of 600 mg/day given twice or three times daily. The chart includes sample sizes for each group and notes statistical significance versus placebo.*

FDA Label Image

Figure 7: Seizure Reduction By Dose (all Partial Onset Seizures) For Studies E1, E2, And E3 (Image 09)

A graph showing seizure reduction as median percentage change from baseline plotted against dose (mg/day). The chart compares multiple studies labeled E1 BD, E2 TID, E3 BD, and E3 TID with data points indicating dose-dependent seizure reduction and associated p-values for significance.*

FDA Label Image

Figure 8: Responder Rate (greater Than Or Equal To 50% Reduction) (Image 10)

A bar chart showing responder rates in percentage for placebo and two doses of Lyrica (pregabalin) at 2.5 mg/kg/day and 10 mg/kg/day. The responder rates increase from placebo (22.6%) to 2.5 mg/kg/day (29.1%) and 10 mg/kg/day (40.6%). Sample sizes for each group are also indicated below the bars.*

FDA Label Image

Figure 9: Patients Achieving Various Levels Of Improvement In Pain Intensity – Fibromyalgia Study F1 (Image 11)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. The graph compares different daily doses of pregabalin (600 mg, 450 mg, 300 mg) and placebo, showing trends of patient improvements across a range of pain reduction percentages.*

FDA Label Image

Figure 10: Time To Loss Of Therapeutic Response, Fibromyalgia Study F2 (kaplan-meier Analysis) (Image 12)

A Kaplan-Meier survival curve graph comparing the estimated percentage of subjects without LTR over 180 days between Pregabalin and placebo groups. The y-axis shows percentage without LTR (0% to 100%), and the x-axis shows time in days from 0 to 180. Pregabalin group maintains a higher percentage of subjects without LTR compared to placebo throughout the period.*

FDA Label Image

Figure 11: Patients Achieving Various Levels Of Improvement In Pain Intensity – Study Sci 1 (Image 13)

A line graph comparing the percentage of subjects improved over time from baseline to week 12. The x-axis shows percent improvement from baseline to week 12 BOCF, and the y-axis shows percent of subjects improved. Two lines represent Pregabalin and Placebo, with Pregabalin showing consistently higher improvement rates.*

FDA Label Image

Figure 12: Patients Achieving Various Levels Of Improvement In Pain Intensity – Study Sci 2 (Image 14)

A line graph showing the percentage of subjects improved over a range of percent improvement from baseline to week 16 BOCF. The x-axis represents percent improvement from baseline to week 16 BOCF, from 0 to 100 percent, and the y-axis represents the percent of subjects improved, from 0 to 100 percent. Two lines compare Pregabalin (solid line) and Placebo (dashed line) groups, showing higher improvement percentages in the Pregabalin group across the range.*

FDA Label Image

Lyrica Capsules 25 mg Bottle Label (Image 15)

Label of Lyrica 25 mg capsules containing pregabalin, indicated for oral use. The label includes storage instructions to keep at 25°C (77°F) with permitted excursions, dispense in child-resistant containers, and a note to always dispense with the medication guide. The package contains 90 capsules and is labeled Rx only by Viatris Specialty LLC.*

FDA Label Image

Lyrica Capsules 50 mg Bottle Label (Image 16)

Lyrica 50 mg capsules label showing the brand name and generic name pregabalin. The label indicates a dosage strength of 50 mg per capsule and a quantity of 90 capsules. It includes storage instructions for controlled room temperature (25°C), a note to dispense in child-resistant containers, and a reminder to always dispense with the medication guide. The label also states Rx only and identifies the labeler as Viatris Specialty LLC.*

FDA Label Image

Lyrica Capsules 75 mg Bottle Label (Image 17)

Lyrica 75 mg capsules label showing the proprietary and generic name (pregabalin). The label includes dosage strength, quantity of 90 capsules, and dispensing instructions. It states storage conditions, dispensing in child-resistant containers, and advises always dispensing with the medication guide. Labeler is Viatris Specialty LLC.*

FDA Label Image

Lyrica Capsules 100 mg Bottle Label (Image 18)

Label for Lyrica 100 mg capsules containing pregabalin, manufactured by Viatris Specialty LLC. The label includes storage instructions to keep at 25°C with permitted excursions, a note to dispense in child-resistant containers, and a dosage advisory to consult prescribing information. The package contains 90 capsules, marked as prescription-only.*

FDA Label Image

Lyrica Capsules 150 mg Bottle Label (Image 19)

Label for Lyrica (pregabalin) capsules, 150 mg strength, containing 90 capsules. The label includes storage instructions specifying 25°C with permitted excursions, dispensing instructions, and states prescription use only. The labeler is Viatris Specialty LLC.*

FDA Label Image

Lyrica Capsules 200 mg Bottle Label (Image 20)

Label for Lyrica (pregabalin) 200 mg oral capsules by Viatris Specialty LLC. The label indicates storage instructions at 25°C (77°F) with permitted excursions, child-resistant container dispensing, and that each capsule contains 200 mg pregabalin. The container holds 90 capsules and is marked Rx only.*

FDA Label Image

Lyrica Capsules 225 mg Bottle Label (Image 21)

Label for Lyrica (pregabalin) capsules, 225 mg strength, by Viatris Specialty LLC. The label states storage instructions, dispensing advice, dosage caution, and confirms each capsule contains 225 mg pregabalin. The package holds 90 capsules and is marked Rx only. A barcode, NDC, and spaces for GTIN, lot number, and expiration date are included.*

FDA Label Image

Lyrica Capsules 300 mg Bottle Label (Image 22)

Label for Lyrica 300 mg capsules (pregabalin) by Viatris Specialty LLC, containing 90 capsules. The label includes storage instructions at 25°C (77°F) with permitted excursions, a note to dispense in child-resistant containers, dosage reference to accompanying prescribing information, and a barcode. Marked Rx only.*

FDA Label Image

Lyrica Oral Solution 20 mg Per mL Carton Label (Image 23)

Packaging label for Lyrica (pregabalin) 20 mg per mL oral solution by Viatris Specialty LLC. The label indicates a 16 fl oz (473 mL) bottle with storage instructions and dosing guidance. It includes warnings to dispense with medication guide and states Rx only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.